Home >Technologies Available >Technologies available for licensing

Predictive biomarkers of cardiac toxicity during chemotherapy

Image from Licence Details: Predictive biomarkers of cardiac toxicity during chemotherapy

Applications: Treatment response biomarker

Predictive SNPs identified from GWAS studies and subsequently validated that predict the likelihood of cardiac related toxicity during 5-fluorouracil (5-FU) or Capecitabine treatment for colorectal, gastric, or breast cancer.

Features Benefits
  • Validated SNPs of cardiac toxicity in response to 5-FU treatment.
  • Improves clinical decision making with regard to treatment choice or degree of monitoring during treatment.
  • Cardiotoxicity is not identified by any of the SNPs in the commonly used 4-SNP DYPD assays for assessing response to 5-FU treatment.
  • Adds new information to existing assays.
  • >79% sensitivity and >91% specificity.
  • High levels of accuracy allow for improved decision-making.
  • 14 different informative SNPs identified.
  • Allows test developers to use SNP most appropriate for their assay.

 

Patented and Available for:

  • Licensing
  • Co-development
  • Consulting
Request more information
about this technology

Back to Technologies Available

Sparks Background Image

Ready to get in touch?

Contact Us
Sparks Background Image
© Oxford University Innovation